BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 32344823)

  • 1. The Effects of Human BDH2 on the Cell Cycle, Differentiation, and Apoptosis and Associations with Leukemia Transformation in Myelodysplastic Syndrome.
    Yang WC; Lin SF; Wang SC; Tsai WC; Wu CC; Wu SC
    Int J Mol Sci; 2020 Apr; 21(9):. PubMed ID: 32344823
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human BDH2, an anti-apoptosis factor, is a novel poor prognostic factor for de novo cytogenetically normal acute myeloid leukemia.
    Yang WC; Tsai WC; Lin PM; Yang MY; Liu YC; Chang CS; Yu WH; Lin SF
    J Biomed Sci; 2013 Aug; 20(1):58. PubMed ID: 23941109
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Matrix metalloproteinase production by bone marrow mononuclear cells from normal individuals and patients with acute and chronic myeloid leukemia or myelodysplastic syndromes.
    Ries C; Loher F; Zang C; Ismair MG; Petrides PE
    Clin Cancer Res; 1999 May; 5(5):1115-24. PubMed ID: 10353746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High Expression of Human Homologue of Murine Double Minute 4 and the Short Splicing Variant, HDM4-S, in Bone Marrow in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome.
    Han X; Medeiros LJ; Zhang YH; You MJ; Andreeff M; Konopleva M; Bueso-Ramos CE
    Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S30-8. PubMed ID: 27155969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SPARC silencing inhibits the growth of acute myeloid leukemia transformed from myelodysplastic syndrome via induction of cell cycle arrest and apoptosis.
    Nian Q; Xiao Q; Wang L; Luo J; Chen LP; Yang ZS; Liu L
    Int J Mol Med; 2014 Apr; 33(4):856-62. PubMed ID: 24535175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mesenchymal stromal cells from myelodysplastic and acute myeloid leukemia patients display in vitro reduced proliferative potential and similar capacity to support leukemia cell survival.
    Corradi G; Baldazzi C; Očadlíková D; Marconi G; Parisi S; Testoni N; Finelli C; Cavo M; Curti A; Ciciarello M
    Stem Cell Res Ther; 2018 Oct; 9(1):271. PubMed ID: 30359303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Isocitrate dehydrogenase 2 mutations correlate with leukemic transformation and are predicted by 2-hydroxyglutarate in myelodysplastic syndromes.
    Lin P; Luo Y; Zhu S; Maggio D; Yang H; Hu C; Wang J; Zhang H; Ren Y; Zhou X; Mei C; Ma L; Xu W; Ye L; Zhuang Z; Jin J; Tong H
    J Cancer Res Clin Oncol; 2018 Jun; 144(6):1037-1047. PubMed ID: 29549529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bone marrow stromal cells from MDS and AML patients show increased adipogenic potential with reduced Delta-like-1 expression.
    Weickert MT; Hecker JS; Buck MC; Schreck C; Rivière J; Schiemann M; Schallmoser K; Bassermann F; Strunk D; Oostendorp RAJ; Götze KS
    Sci Rep; 2021 Mar; 11(1):5944. PubMed ID: 33723276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Over-expression of tumor necrosis factor-alpha in bone marrow biopsies from patients with myelodysplastic syndromes: relationship to anemia and prognosis.
    Stifter G; Heiss S; Gastl G; Tzankov A; Stauder R
    Eur J Haematol; 2005 Dec; 75(6):485-91. PubMed ID: 16313260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long non-coding RNA HOXB-AS3 promotes myeloid cell proliferation and its higher expression is an adverse prognostic marker in patients with acute myeloid leukemia and myelodysplastic syndrome.
    Huang HH; Chen FY; Chou WC; Hou HA; Ko BS; Lin CT; Tang JL; Li CC; Yao M; Tsay W; Hsu SC; Wu SJ; Chen CY; Huang SY; Tseng MH; Tien HF; Chen RH
    BMC Cancer; 2019 Jun; 19(1):617. PubMed ID: 31234830
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of combined MN1, ERG, BAALC, and EVI1 (MEBE) expression in patients with myelodysplastic syndromes.
    Thol F; Yun H; Sonntag AK; Damm F; Weissinger EM; Krauter J; Wagner K; Morgan M; Wichmann M; Göhring G; Bug G; Ottmann O; Hofmann WK; Schambach A; Schlegelberger B; Haferlach T; Bowen D; Mills K; Ganser A; Heuser M
    Ann Hematol; 2012 Aug; 91(8):1221-33. PubMed ID: 22488406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ribosomal protein S14 silencing inhibits growth of acute myeloid leukemia transformed from myelodysplastic syndromes via activating p53.
    Wang L; Luo J; Nian Q; Xiao Q; Yang Z; Liu L
    Hematology; 2014 Jun; 19(4):225-31. PubMed ID: 24074450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DICER1 gene and miRNA dysregulation in mesenchymal stem cells of patients with myelodysplastic syndrome and acute myeloblastic leukemia.
    Ozdogan H; Gur Dedeoglu B; Oztemur Islakoglu Y; Aydos A; Kose S; Atalay A; Yegin ZA; Avcu F; Uckan Cetinkaya D; Ilhan O
    Leuk Res; 2017 Dec; 63():62-71. PubMed ID: 29102598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CircZBTB46 predicts poor prognosis and promotes disease progression of myelodysplastic syndromes and acute myeloid leukemia.
    Li S; Zhao G; Wu W; Li N; Wang Q; Wang W; Song X; Wang X
    Clin Exp Med; 2023 Dec; 23(8):4649-4664. PubMed ID: 37930606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of CDKN1C in the bone marrow of patients with myelodysplastic syndrome and secondary acute myeloid leukemia is associated with poor survival after conventional chemotherapy.
    Radujkovic A; Dietrich S; Andrulis M; Benner A; Longerich T; Pellagatti A; Nanda K; Giese T; Germing U; Baldus S; Boultwood J; Ho AD; Dreger P; Luft T
    Int J Cancer; 2016 Sep; 139(6):1402-13. PubMed ID: 27170453
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survivin expression in "low-risk" and "high-risk" myelodysplastic syndromes.
    Gianelli U; Fracchiolla NS; Cortelezzi A; Pellegrini C; Savi F; Moro A; Grimoldi MG; Deliliers GL; Coggi G; Bosari S
    Ann Hematol; 2007 Mar; 86(3):185-9. PubMed ID: 17124585
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apoptosis, bcl-2 expression and p53 accumulation in myelodysplastic syndrome, myelodysplastic-syndrome-derived acute myelogenous leukemia and de novo acute myelogenous leukemia.
    Kurotaki H; Tsushima Y; Nagai K; Yagihashi S
    Acta Haematol; 2000; 102(3):115-23. PubMed ID: 10692673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Matrix metalloproteinase-9 in plasma of bone marrow aspirates of patients with acute myeloid leukemia and myelodysplastic syndrome].
    Lesnichenko IF; Kostroma II; Gritsaev SV; Chechetkin AV; Abdulkadyrov KM
    Vopr Onkol; 2016; 62(1):101-3. PubMed ID: 30444586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hematopoiesis-related microRNA expression in myelodysplastic syndromes.
    Pons A; Nomdedeu B; Navarro A; Gaya A; Gel B; Diaz T; Valera S; Rozman M; Belkaid M; Montserrat E; Monzo M
    Leuk Lymphoma; 2009 Nov; 50(11):1854-9. PubMed ID: 19883312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RAB27B inhibits proliferation and promotes apoptosis of leukemic cells via 3-Hydroxy butyrate dehydrogenase 2 (BDH2).
    Meng C; Huang L; Fu X; Wu B; Lin L
    Bioengineered; 2022 Mar; 13(3):5103-5112. PubMed ID: 35164665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.